公司概述
Callan JMB Inc., operating under the ticker CJMB, delivers thermal management logistics solutions specifically tailored for the life sciences industry through its subsidiary, Coldchain Technology Services, LLC. The company's core business focuses on providing specialized logistics services and solutions for frozen shipping, which are critical for the transport of personalized medicine and cell therapies. This entity operates within the Industrials sector, specifically in the Integrated Freight & Logistics industry, a classification that denotes its role in the broader supply chain infrastructure supporting temperature-sensitive pharmaceutical products. As of the latest available data, the company possesses a market capitalization of $6.81M and generated total revenue of $5.72M over the trailing twelve months, with no specific employee count disclosed in public records. These financial figures indicate that Callan JMB Inc. functions as a micro-cap enterprise with limited scale relative to large-scale freight conglomerates, suggesting its position as a niche player rather than a dominant market leader within the integrated freight and logistics landscape.
财务健康
The company reported revenue of $5.72M for the trailing twelve months, yet this revenue figure contrasts sharply with a net income of -$7,966,366 and an EBITDA of -$6,340,539, revealing a severe disconnect between top-line sales and bottom-line profitability. This substantial gap between revenue and net income indicates that the company's cost structure includes significant non-operating expenses or one-time charges that are not fully covered by its core operational earnings. Furthermore, the free cash flow stands at -$2,577,123, which implies that the company is currently burning cash and lacks the immediate financial flexibility to fund expansion or return capital to shareholders without external financing. The gross margin is reported at 36.8%, suggesting that the company retains a moderate portion of revenue after direct production costs, while the operating margin of -169.6% and profit margin of -139.2% demonstrate that operating expenses and other costs are exceeding total revenue, resulting in losses on nearly every dollar of sales. Regarding liquidity and leverage, the company holds $2.13M in cash against $1.99M in debt, resulting in a debt-to-equity ratio of 85.36 which characterizes a highly leveraged balance sheet where debt obligations are substantial relative to equity. The current ratio of 2.16 indicates that the company possesses more than double the current assets required to cover its short-term liabilities, suggesting adequate short-term liquidity despite the overall financial losses. Finally, the return on equity is -289.6% and the return on assets is -74.7%, metrics that reveal management is currently destroying value rather than generating returns for equity holders or utilizing assets efficiently to produce profit.
估值评估
The trailing P/E ratio is not available due to negative earnings, and the forward P/E ratio is also not available, meaning traditional earnings-based valuation multiples cannot be used to assess the company's expected earnings trajectory or future profitability expectations. The price-to-book ratio stands at 2.53, which indicates that the market is valuing the company at a significant premium above its tangible book value, despite the entity's current inability to generate positive retained earnings. As an alternative to earnings multiples, the price-to-sales ratio is 1.19 and the EV/EBITDA is -1.05, suggesting that investors are pricing the stock based on revenue generation potential and enterprise value relative to earnings before interest, taxes, depreciation, and amortization, though the negative EV/EBITDA reflects the company's current loss-making status. The stock has traded within a 52-week range between a low of $1.08 and a high of $5.88, with the current price sitting below the upper bound of this historical volatility range. The beta value is not available, so it is impossible to quantify the stock's price volatility relative to the broader market index based on the provided data points.
Growth & Income
The company experienced a revenue decline of 14.1% year-over-year, while earnings growth is not available due to negative earnings, indicating that the business is currently contracting rather than expanding its top line. Since the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute any portion of its earnings to shareholders, instead retaining any available cash flow for internal use or operational needs. The absence of a dividend yield implies that the company reinvests all resources into maintaining its logistics infrastructure or attempting to reverse the negative revenue trend, rather than providing immediate income to investors. Overall, the growth and income profile of Callan JMB Inc. is characterized by declining revenue, negative earnings growth, a lack of dividend payouts, and a valuation that relies on non-traditional metrics due to the absence of positive profitability and available beta data.